TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03425669

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham stimulation
Description: Patients will receive sham stimulation in place of active vestibular stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham stimulation
Description: Patients will receive sham stimulation in place of active vestibular stimulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active medication
Description: Patients will be examined with and without medication.
Study: NCT04088162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Postoperative Negative Pressure Wound Therapy KCI NANOVA
Study: NCT02586376

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 0J LLLT
Description: Sham Low-Level Laser Therapy (Sham LLLT): perform with the machine off.
Study: NCT00151281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEPC
Description: Induction phase (month 1-3)~• PEPC daily (prednisone 20 mg/day, cyclophosphamide 50 mg/day, etoposide 50 mg/day, and procarbazine 50 mg/day) until expected drop in neutrophil count (ANC \< 3000), unless due to disease. After ANC returns to above 2,000/ul, PEPC resumes at alternate day or fractionated weekly basis.~Maintenance phase (month 4-12) • PEPC QOD or fractionated weekly basis.~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• PEPC QOD or fractionated weekly basis
Study: NCT02586376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4J LLLT
Description: 4J Low-Level Laser Therapy (4J LLLT) irradiation will be perform with 4J.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6J LLLT
Description: 6J Low-Level Laser Therapy (6J LLLT) irradiation will be perform with 6J.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8J LLLT
Description: 8J Low-Level Laser Therapy (8J LLLT) irradiation will be perform with 8J.
Study: NCT04021966

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal laser application
Description: One laser treatment cycle consists of 3 vaginal laser applications with a 4-weeks interval. Each application lasts around 5 minutes.~The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~A vaginal probe will be gently inserted and manually rotated to provide a 360° treatment of the vaginal mucosa.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Vaginal laser application
Description: One laser treatment cycle consists of 3 vaginal laser applications with a 4-weeks interval. Each application lasts around 5 minutes.~The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~A vaginal probe will be gently inserted and manually rotated to provide a 360° treatment of the vaginal mucosa.
Study: NCT03301389

Intervention type: OTHER
Intervention: Cardiac magnetic resonance imaging
Description: The cardiac imaging protocol will include pre-contrast T1, post-contrast T1, and T2 mapping images acquired of the mid ventricle with the short axis plane for the analysis of native T1, T2, and extracellular volume (ECV) values of the myocardium. It will also include cine imaging covering the whole LV myocardium in the short axis plane for a functional analysis of the LV myocardium.

Intervention type: OTHER
Intervention: Cardiac magnetic resonance imaging
Description: The cardiac imaging protocol will include pre-contrast T1, post-contrast T1, and T2 mapping images acquired of the mid ventricle with the short axis plane for the analysis of native T1, T2, and extracellular volume (ECV) values of the myocardium. It will also include cine imaging covering the whole LV myocardium in the short axis plane for a functional analysis of the LV myocardium.

Intervention type: OTHER
Intervention: Cardiac magnetic resonance imaging
Description: The cardiac imaging protocol will include pre-contrast T1, post-contrast T1, and T2 mapping images acquired of the mid ventricle with the short axis plane for the analysis of native T1, T2, and extracellular volume (ECV) values of the myocardium. It will also include cine imaging covering the whole LV myocardium in the short axis plane for a functional analysis of the LV myocardium.

Intervention type: OTHER
Intervention: Cardiac magnetic resonance imaging
Description: The cardiac imaging protocol will include pre-contrast T1, post-contrast T1, and T2 mapping images acquired of the mid ventricle with the short axis plane for the analysis of native T1, T2, and extracellular volume (ECV) values of the myocardium. It will also include cine imaging covering the whole LV myocardium in the short axis plane for a functional analysis of the LV myocardium.

Intervention type: OTHER
Intervention: Cardiac magnetic resonance imaging
Description: The cardiac imaging protocol will include pre-contrast T1, post-contrast T1, and T2 mapping images acquired of the mid ventricle with the short axis plane for the analysis of native T1, T2, and extracellular volume (ECV) values of the myocardium. It will also include cine imaging covering the whole LV myocardium in the short axis plane for a functional analysis of the LV myocardium.

Intervention type: OTHER
Intervention: Cardiac magnetic resonance imaging
Description: The cardiac imaging protocol will include pre-contrast T1, post-contrast T1, and T2 mapping images acquired of the mid ventricle with the short axis plane for the analysis of native T1, T2, and extracellular volume (ECV) values of the myocardium. It will also include cine imaging covering the whole LV myocardium in the short axis plane for a functional analysis of the LV myocardium.
Study: NCT01477281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daflon
Description: Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venaflon (Diosmin and Hesperidin)
Description: Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
Study: NCT01913301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alagebrium
Study: NCT01125098

Intervention type: OTHER
Intervention: PRO-CT values
Description: * continue antibiotics for 10 days if a single PRO-CT value is 0.25 mcg/L or greater, that will be judged suggestive of bacterial infection~* continue antibiotics from day 3 to day 10 if one or more PRO-CT values are 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, PLUS acute respiratory failure or clinical instability~* stop antibiotics on day 3, if one or more PRO-CT values are between 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, BUT the patient has not acute respiratory failure or clinical instability~* stop antibiotics if all the PRO-CT values are \< 0.1 mcg/L or if there is a consistent trend to normalization of PRO-CT with the last value \< 0.1 mcg/L, that will be judged suggestive of absence of bacterial infection.
Study: NCT02955875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Description: Outpatient drug history management, drug regimen review, patient counseling and education before and/or after physician evaluation on the day of facility visit
Study: NCT03844659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Song Weightless by Marconi Union
Description: Patients will be randomized to the intervention group (the song Weightless by Marconi Union will be playing) during subjects labor epidural placement. The intervention in this study is solely the addition of music.

Intervention type: OTHER
Group type: OTHER
Intervention: No Song
Description: No song will be played during subjects labor epidural placement.
Study: NCT03011203

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise
Description: In session II and III participants will perform an exercise test on a bicycle inside and outside the MR scanner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical exercise
Description: In session II and III participants will perform an exercise test on a bicycle inside and outside the MR scanner.
Study: NCT00151281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Induction phase (month 1-3)~• Daily thalidomide at 50 mg/day for the first 8 weeks, then dose escalated as tolerated to a maximum of 100 mg/day.~Maintenance phase (month 4-12) • Daily low dose thalidomide (50-100 mg/d)~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• Daily low dose thalidomide (50-100mg/d)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Induction phase (month 1-3)~• Rituximab weekly x 4 (375 mg/m2/week) starting at week 1.~Maintenance phase (month 4-12) • Rituximab (375 mg/m2/week) weekly x 4 administered every 4 months.~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• Rituximab (375 mg/m2/week) weekly x 4 administered every 4 months
Study: NCT03342001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitonin
Description: calcitonin nasal spray
Study: NCT02158689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human menopausal gonadotropin (hMG)
Study: NCT00452374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 1 g/m\^2 given IV for two days (Days 2 and 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 given IV for two days (Days 2 and 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Starting dose of 17.5 mg/m\^2 IV for 4 days (Days 1 through 4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 IV on Day 3 of the first cycle over 4-6 hours and on Day 1 on every cycle following.
Study: NCT02144766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: caudal block with 1 ml/kg of ropivacaine 0.2%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: caudal block with 1 ml/kg of saline
Study: NCT00191243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: A: second line therapy - 1000 mg/m2, IV, day 1 and day 8 q 21 days until disease progression~B: 1000 mg/m2, IV, day 1 and day 8 q 21 days, until treatment failure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: A: second line therapy - 1000 mg/m2, IV, day 1 and day 8 q 21 days until disease progression~B: 1000 mg/m2, IV, day 1 and day 8 q 21 days, until treatment failure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: A: 80 mg/m2, IV, q 21 days until treatment failure followed by second line single agent gemcitabine~B: 80 mg/m2, IV, q 21 days until treatment failure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: A: 80 mg/m2, IV, q 21 days until treatment failure followed by second line single agent gemcitabine~B: 80 mg/m2, IV, q 21 days until treatment failure
Study: NCT03711890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Undergo OCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo resection will be undertaken
Study: NCT03422198

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Cuff Brachytherapy
Description: Undergo standard of care vaginal cuff brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course vaginal cuff brachytherapy
Description: Undergo short course vaginal cuff brachytherapy
Study: NCT04109716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy - Adolescent Skills Training
Description: This is an indicated group depression prevention consisting of 2 individual pre-group sessions, 8 weekly group session, and up to 6 individual booster sessions. IPT-AST will be delivered predominately through telehealth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as usual
Description: Services as usual is expected to be brief periodic sessions (in person or remote) with the school counselor or services in the community.
Study: NCT02614456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon-gamma and nivolumab
Study: NCT04241848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Keeogo
Description: A new and novel type of robotic-device (Keeogo, B-temia, Inc.) was developed to provide powered assistance at the knee for persons with stroke. This device provides assistance for both knee extension and knee flexion during ambulation, transfers to standing and sitting, in addition to ascending and descending stairs. As this device isn't able to fully control the movement, it requires the ability of the patient to stand and initiate stepping. The approach the Keeogo uses to monitor the desired movement in order to appropriately provide assistance. This promotes intuitive learning for the user, minimizing the amount of instruction and practice needed to effectively ambulate allowing users to independently ambulate within one session. This device does not restrict leg movement, so the user can side-step and walk backwards. However, it does not provide assistance during these movements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ambulation training
Description: Ambulation training will consist of mobility activities affecting daily life including: walking; squatting (or getting in and out of a chair); bending, kneeling or stooping (for picking an item up off of the floor); and ascending and descending stairs. Sessions will be monitored and tailored to the individual, based on their functional ability and to ensure their safety.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambulation training
Description: Ambulation training will consist of mobility activities affecting daily life including: walking; squatting (or getting in and out of a chair); bending, kneeling or stooping (for picking an item up off of the floor); and ascending and descending stairs. Sessions will be monitored and tailored to the individual, based on their functional ability and to ensure their safety.
Study: NCT03670966

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
Description: Given via infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplantation
Description: Undergo bone marrow transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Granulocyte Colony-Stimulating Factor
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT02979405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: prophylactic infusion of phenylephrine 40 mcg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phenylephrine
Description: prophylactic infusion of phenylephrine 40 mcg/min
Study: NCT01149577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 06 weeks treatment with Olanzapine in a flexible dosage schedule.
Study: NCT01428232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: implementation of the Baby-Friendly Hospital Initiative
Description: Implementation of BFHI steps 1-9 in maternities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFHI steps 1-9 +well-child clinic
Description: Implementation of BFHI steps 1-9 in maternities and provision of breastfeeding support including culturally appropriate educational messages and metaphors as the ongoing aspect of step 10 in well-child clinic
Study: NCT06728787

Intervention type: DEVICE
Intervention: Robot-Assisted Gait Training
Description: 15 sessions of robot-assisted gait training(LOKOMAT)+ 15 session of usual treatment for a total of 30 sessions in three weeks. 45 minutes for each session.
Study: NCT04193826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Closure
Description: Closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the LAAC device will be performed according to device specific instructions for use based on both TEE guidance, ICE and angiography, femoral access and inter-atrial septum crossing
Study: NCT02712073

Intervention type: OTHER
Intervention: Questionnaire
Description: Self administered questionnaire to evaluate the preparation quality of colonoscopy
Study: NCT02514239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836909
Description: Intravenous Infusion of BI 836909.
Study: NCT03711890

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Laboratory Evaluation
Description: Labs will be obtained to test for cancer cell derived exosomes
Study: NCT03136393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community based dietary counselling
Description: The dietary counseling will be delivered to mothers through group sessions (will include cooking demonstration) and home visits by lay health workers. The counseling will promote foods that are nutritious and locally available and general better food preparation practices. The choices of the foods to be promoted will be based on linear programming results from a preceding survey on dietary intake of pregnant women in the area as well as results of analysis of foods associated with infant birth size (same data). The goal in the linear programming was to find a model of food combinations among the most frequently consumed foods which better meets required intakes during pregnancy. Additionally, adherence to pregnancy iron supplements will also be promoted.
Study: NCT03136393

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community based antenatal counselling
Description: The antenatal counselling will focus on preparations for neonatal care and encouragement for facility based delivery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community based antenatal counselling
Description: The antenatal counselling will focus on preparations for neonatal care and encouragement for facility based delivery.
Study: NCT02355678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: IV 0.5 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthetic infiltration
Description: Using 25 G-3.5 cm curved needle
Study: NCT02355678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Induction by intravenous fentanyl (1.5 µg kg-1) and propofol (2.5 mg kg-1) followed by endotracheal intubation facilitated by atracurium (0.5 mg kg-1).~Maintenance with sevoflurane 1-3%, fentanyl (1-2 µg kg-1), nitrous oxide 70% and oxygen 30%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Induction by intravenous fentanyl (1.5 µg kg-1) and propofol (2.5 mg kg-1) followed by endotracheal intubation facilitated by atracurium (0.5 mg kg-1).~Maintenance with sevoflurane 1-3%, fentanyl (1-2 µg kg-1), nitrous oxide 70% and oxygen 30%.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Description: Mono-polar electrocautery or cold dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Description: Mono-polar electrocautery or cold dissection
Study: NCT02514239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836909
Description: Intravenous Infusion of BI 836909.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836909
Description: Intravenous Infusion of BI 836909.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836909
Description: Intravenous Infusion of BI 836909.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836909
Description: Intravenous Infusion of BI 836909.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836909
Description: Intravenous Infusion of BI 836909.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836909
Description: Intravenous Infusion of BI 836909.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836909
Description: Intravenous Infusion of BI 836909.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836909
Description: Intravenous Infusion of BI 836909.
Study: NCT02355678

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric content suction
Description: By orogastric tube

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric content suction
Description: By orogastric tube
Study: NCT02514239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836909
Description: Intravenous Infusion of BI 836909.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836909
Description: Intravenous Infusion of BI 836909.
Study: NCT00075842

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Valeriana officinalis extract
Description: Given orally
Study: NCT02355678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride
Description: If Visual Analogue Scale was greater than 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride
Description: If Visual Analogue Scale was greater than 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propacetamol hydrochloride
Description: If Visual Analogue Scale was between 4 and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propacetamol hydrochloride
Description: If Visual Analogue Scale was between 4 and 5
Study: NCT00075842

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT03186053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium creatine phosphate
Description: sodium creatine phosphate .Loading dose followed by continuous infusion in operation
Study: NCT02355678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol Suppository
Description: If Visual Analogue Scale was less than 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol Suppository
Description: If Visual Analogue Scale was less than 4